

Cardiology Practice M&A Activity Update

Continued demand for cardiology services coupled with advancements in healthcare technology have primed the market for continued investment and M&A activity

- Cardiology private equity investment has ramped up significantly over the last few years, growing from a few initial investors
 into more than ten platforms today. In 2023 and 2024, add-on transactions accelerated as new platforms continued executing a
 roll-up strategy, resulting in record cardiology transaction volume. The year also included multiple new platform investments
 and exits.
- Key trends in the cardiology landscape include:
 - Focus on Value-Based Care and Outcomes: Emphasis on practices that manage chronic conditions more efficiently and track KPIs such as hospital readmissions.
 - Technological Advancements and Innovation: Advanced diagnostics, minimally invasive procedures, and telemedicine continue to evolve cardiology care.
 - Telehealth and Remote Patient Monitoring: Consultations and post-care check ins continue to utilize telehealth and remote patient monitoring devices to improve access to care and compliance for both providers and patients.
 - Personalized Medicine: Tailored treatment plans around patients own personal health profile and risk factors.
 - o Preventative Care: Practices are offering supplementary services like nutrition advice, exercise programs, and stress management techniques making them a one-stop solution for a comprehensive cardiovascular care plan.

Cardiology Investment Objectives and Opportunities



Operations Experience and Economies of Scale

Economies of scale can take different forms such as bulk purchasing discounts for equipment, professionalization of accounting and revenue cycle management functions, and employee benefits and insurance savings.



Growth Investments

Private equity can help to finance infrastructure investments including the buildout of de-novo outpatient clinics, office-based labs (OBLs), and ambulatory surgery centers (ASCs). Provider recruitment support and capital to fund additional practice acquisitions are additional key targeted growth opportunities.




Diversified Revenue Streams


Private equity can help to finance equipment and devices required to perform ancillary services in-house. Key cardiovascular ancillaries include diagnostic stress testing services, advanced imaging (PET/CT), remote patient monitoring, and cardiac rehab services.



Value-Based Care and Technology Upgrades

Private equity can help invest in the technology infrastructure required to efficiently capture patient outcome data. Well-coordinated, high-quality providers that achieve superior patient outcomes and coordinate preventative care can achieve meaningful increases in profitability by embracing value-based care models.





Recent Cardiology M&A Transactions

2023 was a significant year for add-on transactions and the launch of several new platforms


Closed Date	Target Name	Target Location	Acquirer Name	
Oct-24	Birmingham Heart Clinic	AL	US Heart & Vascular (Ares Management; Rubicon Founders)	
Aug-24	Dr Ken Zelnick and Dr Kathir Subramanian	FL	Cardiovascular Associates of America (Webster Equity)	
Jul-24	Florida Cardiology Group	FL	NYU Langone Health	
Jun-24	Ventura Heart Institute	CA	Interventional Cardiology Medical Group	
May-24	Cardiac Rhythm Center	TX	CLS Health	
Apr-24	Atria Heart	AZ	Cardiovascular Associates of America	
Mar-24	CardioOne	NY	WindRose Health Investors	
Feb-24	Cardiovascular Associates	AL	USA Health	
Feb-24	Cardiology Associates of Northern New York	NY	Samaritan Medical	
Feb-24	St. Louis Heart and Vascular	MO	Heart & Vascular Partners (Assured Healthcare Partners)	
Jan-24	CardioHealth	FL	Cardiovascular Logistics (Lee Equity)	
Jan-24	National Cardiovascular Partners	TX	Undisclosed	
Oct-23	Ventricle Health	NC	RA Capital Management; Waterline Ventures	
Oct-23	Clearwater Cardiovascular Consultants	FL	Cardiovascular Logistics	
Sep-23	Practice of Ivor L. Geft, M.D.	CA	MDVIP	
Sep-23	Southeast Houston Cardiology	TX	CLS Health	
Sep-23	Daytona Heart Group	FL	Cardiovascular Associates of America	
Sep-23	The Cardiovascular Center of Florida	FL	Cardiovascular Associates of America	
Sep-23	Central Florida Cardiology Group	FL	QOROS (Chicago Pacific Founders)	
Jul-23	Pivotal Healthcare Partners	FL	SCA Health (Optum)	
Jul-23	Cardiovascular Associates	FL	Cardiovascular Associates of America	
Jun-23	Bay Area Cardiology Associates	FL	Cardiovascular Associates of America	
Jun-23	James River Cardiology	VA	RC Capital	
Jun-23	Shore Heart Group	NJ	Cardiovascular Associates of America	
May-23	Advanced Heart Group	IL	Heart & Vascular Partners	
May-23	Memorial Katy Cardiology Associates	TX	US Heart & Vascular	
May-23	US Heart and Vascular (Ares Management)	Multiple	Rubicon Founders	
May-23	Colorado Springs Cardiology	СО	US Heart & Vascular	
May-23	Dallas Heart & Vascular	TX	US Heart & Vascular	
Apr-23	Novocardia (Deerfield)	Multiple	Cardiovascular Associates of America	
Apr-23	CardiaStream	TX	CHRISTUS Health	
Apr-23	HeartPlace	TX	US Heart and Vascular	
Apr-23	First Coast Cardiovascular Institute	FL	Cardiovascular Logistics	
Apr-23	Heartland Cardiology	KS	US Heart and Vascular	
Apr-23	The Cardiac and Vascular Institute	FL	Cardiovascular Associates of America	
Feb-23	St. John's Vein Center	FL	Pivotal Healthcare Partners	
Feb-23	Orion Medical	TX	US Heart and Vascular	
Feb-23	Mountain View Clinic	AR	Mena Regional Health System	
Feb-23	Cardiovascular Institute Of Central Florida	FL	Cardiovascular Associates of America	
Jan-23	Cardiovascular Institute Of The South	LA	Lee Equity Partners	

Sources: Capital IQ, Press releases, Pitchbook.

Cardiology Practice Platform Landscape

Momentum in cardiology consolidation has built over the last 24 months as the sector continues to receive significant private equity attention

- Since 2022 the number of PE-backed cardiology platforms has more than doubled. Platform operations have grown to span over 20 states in the U.S. with particular focus in the Florida and Texas markets.
- Notably, CVAUSA (backed by Webster Equity Partners), Cardiovascular Logistics (backed by Lee Equity), and Heart and Vascular Partners (backed by Assured Healthcare Partners) have grown quickly to be amongst the largest consolidators in the market by both number of practices under management and geographic coverage.
- While PE-backed platforms have been leading the volume uplift, several strategic companies have also been active in 2023 and 2024. Fresenius divested its cardiology entity National Cardiovascular Partners, and NYU Langone acquired Florida Cardiology Group.
- The trend of strategic acquisitions and private equity investments continued robustly into 2024, highlighting the substantial interest and growth opportunities within the cardiovascular care specialty.
- The Southeast region of the U.S., particularly Texas and Florida, remains a focal point for activity, with multiple platforms deeply invested in these states.



Note: (1) Information presented sourced from publicly announced transactions. Excludes strategic-owned market participants.

Cardiology Tailwinds Driving Investment Interest

Strong sector tailwinds and expansion dynamics signal 'hearty' growth opportunities for cardiology practices in the U.S.

The cardiology physician's market in the U.S. was estimated to generate approximately \$60 billion in 2023 and is expected to grow at a CAGR of 2.6 percent between 2023 to 2028.⁽¹⁾

With the graying American population, demand for internal medicine subspecialties (such as cardiology) treating conditions often associated with age, remains robust.

- The number of adults aged 65 and older is projected to increase from approximately 48 million to over 88 million by 2050.⁽²⁾
- Adults over the age of 60 years contribute to approximately 89 percent of the practice revenue.⁽¹⁾

Underlying medical conditions increasing the prevalence of heart diseases include diabetes, hypertension, and obesity.⁽³⁾


- An estimated 98 million adults have prediabetes.
- The prevalence of obesity was 47.1 percent in 2017- March 2020.
- · Nearly 120 million U.S. adults have hypertension.


As of 2023, there were 34,098 active number of cardiologists in the U.S.⁽⁴⁾

 As demand for cardiovascular services is growing and a large number of active cardiologists are nearing retirement, the estimated deficit of cardiologists in the U.S. is expected to reach 7,080 physicians, by 2025.⁽⁵⁾


The specialty has witnessed an increasing trend towards the provision of cardiovascular procedures in the outpatient setting, particularly in ASC's.

- This trend is largely driven by CMS's ruling finalizing the addition of multiple cardiovascular CPT codes to the list of covered ASC surgical procedures.
- This is further supported by lower costs of procedures in outpatient facilities and advancements of outpatient technologies.










Cardiovascular surgeons, invasive cardiologist and non-invasive cardiologists generate **8.7x**, **5.9x**, and **5.4x** of their respective salaries





Sources:

(1) IBISWorld industry report, "Cardiologists"; (2) U.S. Census Bureau; (3) Centers for Disease Control; (4) Statista; (5) Merritt Hawkins; (6) Active practices with at least 1 physician and main specialty of cardiology per Definitive Healthcare; (7) Heart Disease and Stroke Statistical Update Fact Sheet At-a-Glance (2021).

KPMG Corporate Finance LLC Transactions







Closed





























Closed







KPMG Corporate Finance LLC Healthcare Investment Banking Team



Walter J. Olshanski Managing Director, **Sector Lead** T: 332-259-3301 E: wolshanski@kpmg.com



Jason Moran **Managing Director** T: 415-418-8474 E: jasonmoran@kpmg.com



Adrian Susmano **Managing Director** T: 470-618-5420 E:asusmano@kpmg.com



Michael Cordaro Vice President T: 551-588-1642 E:mcordaro@kpmg.com



Brian Flanagan Vice President T: 464-206-9340 E: blfanagan1@kpmg.com



Patrick Masciangelo Vice President T: 464-206-9348 E: pmasciangelo@kpmg.com



Nicholas A. Schmidt Senior Associate T: 312-550-0968 E: naschmidt@kpmg.com

KPMG Corporate Finance(1)

2,000+

Closed Transactions in the Last 5 Years

2,500+

Global Corporate Finance Professionals

2004-2023 global advisor ranking ⁽²⁾ # of Deals			
1.	КРМС	9,173	
2.	PricewaterhouseCoopers	8,905	
3.	Houlihan Lokey	6,581	
4.	Deloitte	6,111	
5.	Ernst & Young LLP	5,564	
6.	UBS	5,457	
7.	Rothschild & Co	5,364	
8.	Lazard	3,774	
9.	Goldman Sachs & Co	3,729	
10.	JP Morgan	3,604	

KPMG Corporate Finance LLC

80+

U.S. Corporate Finance Professionals



Middle Market Investment Bank

of the Year 2021









Global coverage. Industry knowledge. Middle-Market focus.

KPMG Corporate Finance LLC was recently named Transaction Advisory Firm of the Year by The Global M&A Network and was previously named investment Bank of the Year by the M&A Advisor. KPMG Corporate Finance LLC provides a broad range of investment banking and advisory services to its domestic and international clients. Our professionals have the experience and depth of knowledge to advise clients on global mergers and acquisitions, sales and divestitures, buyouts, financings, debt restructurings, equity recapitalizations, infrastructure project finance, capital advisory, portfolio solutions, fairness opinions, and other advisory needs.

(1) Refers to the global KPMG member firms of the KPMG International network of independent member firms; (2) League tables include completed deals which have value between \$0 million to \$500 million and also where deal value is not disclosed, as of January 2024. *Represents the global Corporate Finance practice of KPMG International's network of independent member firms



Important notice

The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation. The information contained in this communication does not constitute a recommendation, offer, or solicitation to buy, sell or hold any security of any issuer. Past performance does not guarantee future results.

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.

Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.